Literature DB >> 8432869

Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA.

Z Wang1, Y Cao, A P Albino, R A Zeff, A Houghton, S Ferrone.   

Abstract

The lack of HLA class I antigen expression by the melanoma cell line SK-MEL-33 is caused by a unique lesion in beta 2-microglobulin (beta 2-mu). Sequencing of beta 2-mu mRNA detected a guanosine deletion at position 323 in codon 76 that causes a frameshift with a subsequent introduction of a stop codon at a position 54 base upstream of the normal position of the stop codon in the message. The loss of 18 amino acids and the change of 6 amino acids, including a cysteine at position 80 in the carboxy terminus of beta 2-mu, are likely to cause marked changes in the structure of the polypeptide. The latter may account for the inability of beta 2-mu to associate with HLA class I heavy chains and for its lack of reactivity with the anti-beta 2-mu mAb tested. HLA class I antigen expression on SK-MEL-33 cells was reconstituted after transfection with a wild-type B2m gene, therefore indicating that the abnormality of endogenous B2m gene is the only mechanism underlying lack of HLA class I antigen expression by SK-MEL-33 cells. The guanosine deletion in B2m gene was detected also in the melanoma tissue from which SK-MEL-33 cells had originated. Therefore, the molecular lesion identified in the SK-MEL-33 melanoma cell line is not caused by a mutation acquired during growth in vitro but is likely to reflect a somatic mutation during tumor progression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8432869      PMCID: PMC288010          DOI: 10.1172/JCI116249

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia.

Authors:  R K Saiki; S Scharf; F Faloona; K B Mullis; G T Horn; H A Erlich; N Arnheim
Journal:  Science       Date:  1985-12-20       Impact factor: 47.728

2.  Mutations that impair a posttranscriptional step in expression of HLA-A and -B antigens.

Authors:  R DeMars; R Rudersdorf; C Chang; J Petersen; J Strandtmann; N Korn; B Sidwell; H T Orr
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

3.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess.

Authors:  T Lindmo; E Boven; F Cuttitta; J Fedorko; P A Bunn
Journal:  J Immunol Methods       Date:  1984-08-03       Impact factor: 2.303

4.  Production and properties of monoclonal antibodies to guinea pig Ia antigens.

Authors:  S E Zweig; E M Shevach
Journal:  Methods Enzymol       Date:  1983       Impact factor: 1.600

5.  Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules.

Authors:  M A Pellegrino; A K Ng; C Russo; S Ferrone
Journal:  Transplantation       Date:  1982-07       Impact factor: 4.939

6.  Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin.

Authors:  S V Suggs; R B Wallace; T Hirose; E H Kawashima; K Itakura
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

7.  "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

8.  Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation.

Authors:  M C Turco; M De Felice; L Corbo; G Morrone; R Mertelsmann; S Ferrone; S Venuta
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  The absence of beta 2-microglobulin in Daudi cells: active gene but inactive messenger RNA.

Authors:  C de Préval; B Mach
Journal:  Immunogenetics       Date:  1983       Impact factor: 2.846

10.  The CTAB-DNA precipitation method: a common mini-scale preparation of template DNA from phagemids, phages or plasmids suitable for sequencing.

Authors:  G Del Sal; G Manfioletti; C Schneider
Journal:  Biotechniques       Date:  1989-05       Impact factor: 1.993

View more
  19 in total

1.  Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.

Authors:  Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

Review 2.  Immunosuppressive strategies that are mediated by tumor cells.

Authors:  Gabriel A Rabinovich; Dmitry Gabrilovich; Eduardo M Sotomayor
Journal:  Annu Rev Immunol       Date:  2007       Impact factor: 28.527

3.  The heavy chain of neonatal Fc receptor for IgG is sequestered in endoplasmic reticulum by forming oligomers in the absence of beta2-microglobulin association.

Authors:  Xiaoping Zhu; Junmin Peng; Raktima Raychowdhury; Atsushi Nakajima; Wayne I Lencer; Richard S Blumberg
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

4.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

5.  Synthesis of beta(2)-microglobulin-free, disulphide-linked HLA-G5 homodimers in human placental villous cytotrophoblast cells.

Authors:  Pedro J Morales; Judith L Pace; Jeralyn Sue Platt; Daudi K Langat; Joan S Hunt
Journal:  Immunology       Date:  2007-05-02       Impact factor: 7.397

6.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

7.  HLA associations in the antitumor response against malignant melanoma.

Authors:  F M Marincola; P Shamamian; L Rivoltini; M Salgaller; J Cormier; N P Restifo; T B Simonis; D Venzon; D E White; D R Parkinson
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-11

8.  Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.

Authors:  M K Jakobsen; N P Restifo; P A Cohen; F M Marincola; L B Cheshire; W M Linehan; S A Rosenberg; R B Alexander
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1995-05

9.  Prostate cancer health disparities: An immuno-biological perspective.

Authors:  Sanjay Kumar; Rajesh Singh; Shalie Malik; Upender Manne; Manoj Mishra
Journal:  Cancer Lett       Date:  2017-11-15       Impact factor: 8.679

10.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.